The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2024 | Mezigdomide + dexamethasone in novel combinations for R/R myeloma: insights into the CA057-003 trial
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses novel combinations being explored with mezigdomide for relapsed/refractory (R/R) multiple myeloma in the CA057-003 trial (NCT05372354). He shares the promising response rates that have been observed when combining a mezigdomide plus dexamethasone backbone with several novel agents, namely tazemetostat and trametinib. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
